Danaher (NYSE: DHR) has generated investment returns of around 200,000% over the last 40 years, outpacing the broader stock market by several multiples. The firm remains less famous than the major technology giants, but its record of creating value for shareholders ranks among the best in the world. Since its move into manufacturing in 1984, the firm has turned a small sum into a fortune by mastering a disciplined system of buying and improving companies.
This firm shows how a steady focus on process can change even the most unpromising assets into a strong competitive advantage. It moved from its early days as a failing property firm to its current status as a leading healthcare-equipment provider when the founders shifted from corporate raiding to a more patient model of long-term compounding. To understand the current success of this business, one must first look back at the lessons learned during its high-stakes beginnings.
Sign up to Money Morning
Don’t miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don’t miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Danaher’s lessons from Warren Buffett
This unsuccessful bid taught the brothers that hostility and excessive debt often destroyed the very value they wanted to capture. This loss prompted a new way of thinking and they began to pursue businesses with a durable competitive advantage that they could hold for decades. This shift occurred during a fishing trip that the Rales brothers took at Danaher Creek in Montana. The name change to that of the river reflected a move away from asset-stripping. The business began to pivot from being a collection of random businesses into a conglomerate of niche plays. By targeting companies with dominant positions in small markets, Danaher applied a consistent system to drive growth over many years. It remained important to secure attractive deals, but the emphasis shifted away from financing concerns towards expanding profit margins and strengthening the competitive positions of newly acquired businesses.
By 1990, the brothers completed the transition of Danaher into a professional investment machine. Mitchell and Steven Rales stepped back from executive roles to become board members, acting as stewards of the company rather than its daily managers. By hiring professional leaders to run operations, the founders focused entirely on the broader investment strategy. This enabled Danaher to evolve into a platform designed to acquire high-quality businesses and manage them with care. The strategy was set, but the company required a rigorous process to ensure these new acquisitions improved after the purchase.
Danaher solved this operational challenge through the Danaher Business System, or DBS. This framework serves as the organisation’s central guiding operating system. In the late 1980s, the leadership looked to Japan to understand why Toyota outperformed American car companies. They discovered the concept of kaizen, or continuous improvement. Ironically, Japanese corporations had adopted American business styles in developing kaizen, so, in a sense, Danaher was merely repatriating US ideals. While other Western firms viewed this as a tool for the factory floor, Danaher’s bosses adopted it as a universal management philosophy. They applied the concept to every corner of the business, from factories to the head office.
The system rests on four central pillars: people, plan, process and performance. This framework mandates a culture where associates spend most of their time on execution rather than on analysing results. This approach prevents the common corporate trap of “analysis paralysis”. One important component is hoshin kanri, or “compass management”. This ensures every part of the business points toward the same goal. It aligns the board’s strategy with the daily tasks of every employee to ensure everyone pulls in the same direction.
DBS operates as an underpinning philosophy embedded in the way that every unit runs, rather than simply a manual or a newsletter that people might ignore. Even the board members regularly spend entire weeks leading kaizen events on factory floors to identify and eliminate waste. By focusing on the place where the work happens, known in Japanese as gemba, the firm stays grounded in reality. This commitment to process ensures that every acquisition quickly improves to generate superior margins and predictable growth. This internal engine has allowed the business to transition between industries without losing its competitive edge.
Danaher has moved from purely industrial businesses towards areas with long-term competitive advantages, specifically life sciences and diagnostics. The business operates a “picks-and-shovels” model, choosing the firms that provide the essential tools for research rather than taking the risks associated with drug development. If a pharmaceutical company fails to bring a new cure to market, they can lose everything. Danaher sells the filters and resins that laboratories need regardless of which specific drug wins approval. This creates a steady revenue stream tied to the broader growth of global healthcare.
The biotechnology branch drives much of the growth. Through its brands Cytiva and Pall, the firm dominates the production of monoclonal antibodies. These complex medicines treat diseases such as cancer and migraines, and were vital during the pandemic. They also feature in everyday laboratory testing, most notably in pregnancy tests. The equipment is specified into the drug manufacturing process itself. Once a medicine wins regulatory approval, the specific filters and components used to produce it are locked in. Switching to a rival supplier would require a long and costly review of the entire factory process. The diagnostics division offers a similar edge. This creates a high degree of certainty for future sales. It moves the business away from the unpredictable cycles of heavy industry towards a more reliable stream of income and this focus on non-discretionary health trends has lowered the long-term risk profile of the business.
A professional acquisition machine
Danaher functions as a professional acquisition machine, which avoids buying businesses simply for the sake of growth. Instead, it follows a rigorous plan to identify markets where it can create a sustainable competitive advantage. These acquisitions fall into two main categories: platforms representing foundational entries into vast new industries that serve as a base for future expansion; and bolt-ons, or smaller firms designed to fill specific technical gaps. The group merges these smaller companies into existing divisions to remove overheads and share technology.
A high level of discipline dictates the price paid for these assets. Every potential deal is measured against a strict financial goal, where the business must produce a 10% return on invested capital by its fifth year. Management specifically looks for businesses with high gross margins, but low operating profits. A high gross margin suggests the product is vital to the customer. A low profit margin suggests the business is being run inefficiently. This gap represents the opportunity for improvement. By applying the Danaher Business System, the firm often doubles the margins of a new arrival within three to five years.
The DBS Office manages this transformation. This team of internal specialists helps new staff adopt the company culture. This requires employees to spend 70% of their time defining a problem and only 30% on the solution. This ensures the team fixes the root cause of an issue rather than just the symptoms. This explains the success rate, which far exceeds the industry average.
The business has faced setbacks during its growth. The acquisition of Cepheid, which became famous for producing rapid Covid tests, succeeded by scaling a niche provider into a global leader in diagnostics. However, other areas proved more difficult. The bioprocessing inventory glut of 2023 and 2024 presented a recent challenge. During the pandemic, customers over-ordered supplies to avoid shortages. This led to lower sales in the post-pandemic world as those stocks were used up. The firm was caught off-guard by the speed of this shift, leading to frustration among some investors.
Learning from mistakes made internally has also shaped the company. In the past, subsidiary managers made mistakes by focusing too much on specific tools of improvement while losing sight of the broader strategy. These managers would lead kaizen events to fix minor floor issues without ensuring they aligned with the long-term plan. This led the parent organisation to refine its “strategic compass” to ensure every change serves a clear purpose. These challenges forced Danaher to become more transparent and to improve its forecasting to prevent a repeat of such supply-chain shocks.
The firm is currently positioning itself at the frontier of genomic medicine. By using a platform approach, the group aims to standardise the way new cures are made. This is often compared to a burrito, where the outer wrap remains the same while the filling changes. This method could significantly lower the time and cost of treating rare diseases. By integrating artificial intelligence, the firm is creating a digital backbone for the industry. Furthermore, the acquisition of Masimo, a leader in pulse oximetry, allows the firm to capture vital data directly from the patient at the hospital bedside.
Danaher is a much larger organisation today than it was in its industrial beginnings, suggesting that a repeat of the 200,000% return over the next 40 years is improbable. Nevertheless, it remains one of the best businesses in the world at identifying, buying and managing assets. Its unique culture and the rigorous application of its business system set it apart. The astronomical gains of the past may be behind it, but the firm remains an excellent choice for those seeking a high-quality investment.
This article was first published in MoneyWeek’s magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Explore More
